Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Stay focused on the facts

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Mar 23, 2022 10:52am

90 Views

Post# 34537628

RE:RE:RE:RE:RE:RE:Stay focused on the facts

They were way off on timelines. Back last June they were talking about reaching MTD at the begining od the fall, so October. Then they revised it to begining of 2022. And now it's something like May 2022. You want to know why the SP is down. You cannot be so bad in your guidance on timelines. Add they changed their tune on NASH and stagnant commercial business. I am glad they changed their tune on NASH, but still, for the time being, they look very bad. They have nothing positive to put forward. They were way too optimistic and got a very bad phase Ia protocol with the FDA. They started at 1/7 of the MTD of docetaxel alone. This made no sense. And the all comers requirement made no sense either. Maybe that they had no choice but to accept those silly requirements from the FDA, but the result is a phase Ia that would have taken 14 months. This is crazy for a PDC using a well know cytotoxic drug (docetaxel).

PWIB123 wrote: Did they actually say all went smoothly? I don't recall hearing that, especially considering they released and acknowledged the neutropenia. I do remember them saying that the things they were seeing were consistent with preclinical.

canadapiet wrote:
And they lied again!!!!!!!

They said the P1a all went smoothly, just like in the preclinicals............!

Look at where we are now..........
How long are the "people in the know" saying that there is "HOPE" ?????
Well, let us all "HOPE" that in the near future (?????again....) we can set a new high !!

Momo25 - (3/23/2022 9:54:30 AM)

RE:RE:RE:Stay focused on the facts

I bought THTX when Trogarzo was lunched. At that time Dubuc talked about a potential of at least 1 billion revenue. Then everything becomes inconsistent. Legacy drugs are covering for the costs only. NASH needs huge investment and big pharmas who are making money like ever are reluctant to put a penny in this program. Oncology was brought to the table since they bought katana and the results up to now are very tiny, if not insignificant.
I averaged down many times and i am still a bit below 6$ and I took a hit of 49k by selling half of my THTX portfolio. Many shhareholders are in the same situation where I am. This is our reality today. The rest is bla..bla